Boris Draznin
Concepts (590)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin | 99 | 2025 | 2524 | 3.970 |
Why?
| | Hyperglycemia | 12 | 2025 | 381 | 3.230 |
Why?
| | Diabetes Mellitus | 16 | 2025 | 1101 | 3.100 |
Why?
| | Insulin Resistance | 32 | 2013 | 1247 | 2.470 |
Why?
| | Phosphatidylinositol 3-Kinases | 17 | 2012 | 384 | 2.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 23 | 2006 | 250 | 1.950 |
Why?
| | Adipocytes | 13 | 2008 | 223 | 1.730 |
Why?
| | Receptor, Insulin | 26 | 2003 | 92 | 1.710 |
Why?
| | Blood Glucose | 27 | 2025 | 2357 | 1.650 |
Why?
| | Alkyl and Aryl Transferases | 14 | 2003 | 31 | 1.550 |
Why?
| | Diabetes Mellitus, Type 2 | 18 | 2025 | 2623 | 1.550 |
Why?
| | Hypoglycemic Agents | 17 | 2025 | 1411 | 1.540 |
Why?
| | Insulin, Long-Acting | 4 | 2020 | 65 | 1.380 |
Why?
| | Hyperinsulinism | 11 | 2009 | 115 | 1.210 |
Why?
| | Calcium | 21 | 2007 | 1181 | 1.040 |
Why?
| | Protein Prenylation | 11 | 2006 | 19 | 0.960 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2007 | 449 | 0.950 |
Why?
| | Adipose Tissue | 19 | 2007 | 641 | 0.890 |
Why?
| | Phosphorylation | 32 | 2013 | 1717 | 0.810 |
Why?
| | Insulin Receptor Substrate Proteins | 15 | 2013 | 55 | 0.780 |
Why?
| | Signal Transduction | 25 | 2012 | 5234 | 0.760 |
Why?
| | Muscle, Skeletal | 11 | 2012 | 1795 | 0.750 |
Why?
| | Rats | 69 | 2007 | 5574 | 0.740 |
Why?
| | Hospitalization | 6 | 2025 | 2468 | 0.720 |
Why?
| | Cytosol | 16 | 1994 | 215 | 0.640 |
Why?
| | Insulin Glargine | 4 | 2014 | 88 | 0.640 |
Why?
| | Obesity | 15 | 2013 | 3123 | 0.630 |
Why?
| | Monosaccharide Transport Proteins | 9 | 2003 | 55 | 0.620 |
Why?
| | Epidemics | 1 | 2021 | 97 | 0.600 |
Why?
| | Inpatients | 3 | 2013 | 538 | 0.590 |
Why?
| | Animals | 106 | 2013 | 38030 | 0.560 |
Why?
| | Glucose | 25 | 2006 | 1051 | 0.550 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 209 | 0.550 |
Why?
| | Proteins | 15 | 2001 | 1021 | 0.550 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2006 | 271 | 0.530 |
Why?
| | Enzyme Inhibitors | 13 | 2007 | 820 | 0.530 |
Why?
| | Dietary Fats | 5 | 2012 | 307 | 0.520 |
Why?
| | Platelet-Derived Growth Factor | 4 | 2003 | 85 | 0.510 |
Why?
| | Deoxyglucose | 10 | 2008 | 51 | 0.500 |
Why?
| | Endocrinology | 1 | 2018 | 77 | 0.500 |
Why?
| | 3T3-L1 Cells | 5 | 2008 | 36 | 0.480 |
Why?
| | Adiponectin | 4 | 2009 | 243 | 0.480 |
Why?
| | Diabetes Mellitus, Type 1 | 8 | 2020 | 3930 | 0.470 |
Why?
| | Insulin-Like Growth Factor I | 11 | 2005 | 318 | 0.460 |
Why?
| | Phosphoproteins | 10 | 2007 | 319 | 0.460 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 80 | 0.460 |
Why?
| | Enteral Nutrition | 3 | 2013 | 212 | 0.460 |
Why?
| | Protein Kinases | 3 | 2008 | 311 | 0.450 |
Why?
| | Somatostatin | 13 | 2001 | 54 | 0.440 |
Why?
| | Islets of Langerhans | 17 | 1991 | 852 | 0.430 |
Why?
| | Triglycerides | 3 | 2012 | 527 | 0.430 |
Why?
| | Farnesyltranstransferase | 11 | 2009 | 21 | 0.430 |
Why?
| | Insulin, Isophane | 2 | 2013 | 22 | 0.430 |
Why?
| | Growth Hormone | 8 | 2007 | 91 | 0.430 |
Why?
| | Academic Medical Centers | 1 | 2018 | 560 | 0.420 |
Why?
| | Patient Care Planning | 1 | 2016 | 170 | 0.420 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2025 | 704 | 0.420 |
Why?
| | Rats, Inbred Strains | 26 | 1992 | 316 | 0.410 |
Why?
| | Dietary Carbohydrates | 3 | 2012 | 145 | 0.410 |
Why?
| | 3T3 Cells | 13 | 2007 | 152 | 0.410 |
Why?
| | Phosphates | 3 | 2007 | 175 | 0.410 |
Why?
| | Glucocorticoids | 2 | 2016 | 536 | 0.410 |
Why?
| | Cells, Cultured | 25 | 2008 | 4112 | 0.410 |
Why?
| | Humans | 69 | 2025 | 145625 | 0.400 |
Why?
| | Guanosine Triphosphate | 12 | 2000 | 88 | 0.390 |
Why?
| | Medically Uninsured | 1 | 2014 | 134 | 0.380 |
Why?
| | Muscle Proteins | 4 | 2012 | 242 | 0.380 |
Why?
| | Kinetics | 24 | 2012 | 1553 | 0.380 |
Why?
| | Liver | 15 | 2009 | 1859 | 0.370 |
Why?
| | Continuity of Patient Care | 2 | 2019 | 297 | 0.360 |
Why?
| | Sirtuin 1 | 1 | 2012 | 35 | 0.360 |
Why?
| | Enzyme Activation | 10 | 2008 | 758 | 0.360 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1581 | 0.360 |
Why?
| | Muscles | 3 | 2004 | 330 | 0.350 |
Why?
| | Diabetes Mellitus, Experimental | 5 | 1992 | 198 | 0.350 |
Why?
| | Biphasic Insulins | 1 | 2011 | 3 | 0.350 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 3 | 2007 | 56 | 0.350 |
Why?
| | Patient Preference | 1 | 2014 | 224 | 0.340 |
Why?
| | Insulin Lispro | 1 | 2011 | 44 | 0.340 |
Why?
| | Cystic Fibrosis | 2 | 2012 | 1164 | 0.340 |
Why?
| | Cell Membrane | 18 | 2003 | 701 | 0.340 |
Why?
| | Decision Making | 2 | 2018 | 987 | 0.330 |
Why?
| | Methylprednisolone | 1 | 2011 | 58 | 0.320 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 192 | 0.320 |
Why?
| | Atherosclerosis | 4 | 2019 | 410 | 0.320 |
Why?
| | Thiazolidinediones | 2 | 2008 | 142 | 0.320 |
Why?
| | Patient Care Team | 1 | 2016 | 700 | 0.320 |
Why?
| | Patient Admission | 1 | 2012 | 216 | 0.310 |
Why?
| | Mice | 28 | 2009 | 18266 | 0.310 |
Why?
| | Blotting, Western | 9 | 2012 | 1176 | 0.310 |
Why?
| | Phosphoprotein Phosphatases | 4 | 1995 | 67 | 0.310 |
Why?
| | Hospitals | 2 | 2013 | 730 | 0.310 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2011 | 2018 | 0.310 |
Why?
| | Receptors, Cell Surface | 12 | 1986 | 371 | 0.310 |
Why?
| | Epidermal Growth Factor | 6 | 1998 | 157 | 0.310 |
Why?
| | Pituitary Gland, Anterior | 5 | 1988 | 37 | 0.300 |
Why?
| | Biomarkers | 3 | 2020 | 4329 | 0.300 |
Why?
| | Phosphoric Monoester Hydrolases | 4 | 1994 | 59 | 0.300 |
Why?
| | Medicaid | 1 | 2014 | 472 | 0.300 |
Why?
| | Adaptor Proteins, Signal Transducing | 5 | 2001 | 427 | 0.290 |
Why?
| | Male | 57 | 2025 | 73014 | 0.290 |
Why?
| | rhoA GTP-Binding Protein | 4 | 2003 | 76 | 0.290 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 14 | 0.290 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 3 | 2001 | 146 | 0.290 |
Why?
| | Quality Improvement | 2 | 2018 | 1325 | 0.280 |
Why?
| | MAP Kinase Signaling System | 3 | 2006 | 306 | 0.280 |
Why?
| | Gene Expression Regulation, Enzymologic | 4 | 2005 | 266 | 0.280 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 122 | 0.280 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2008 | 12 | 0.280 |
Why?
| | DNA-Binding Proteins | 5 | 2004 | 1467 | 0.280 |
Why?
| | Cyclic AMP | 9 | 1993 | 208 | 0.270 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1997 | 165 | 0.270 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 952 | 0.270 |
Why?
| | Mitochondrial Diseases | 1 | 2008 | 94 | 0.260 |
Why?
| | Algorithms | 1 | 2016 | 1843 | 0.260 |
Why?
| | Transfection | 9 | 2008 | 914 | 0.260 |
Why?
| | Diabetic Angiopathies | 2 | 2007 | 265 | 0.260 |
Why?
| | Adult | 20 | 2025 | 40821 | 0.260 |
Why?
| | Leukocytes | 2 | 2006 | 301 | 0.250 |
Why?
| | Pregnancy Proteins | 2 | 2005 | 36 | 0.250 |
Why?
| | Androstadienes | 5 | 2008 | 77 | 0.250 |
Why?
| | Early Growth Response Protein 1 | 2 | 2006 | 32 | 0.240 |
Why?
| | Phosphoserine | 1 | 2006 | 25 | 0.240 |
Why?
| | src Homology Domains | 2 | 2003 | 34 | 0.240 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 63 | 0.240 |
Why?
| | Organophosphonates | 2 | 1997 | 95 | 0.240 |
Why?
| | Middle Aged | 18 | 2025 | 36359 | 0.240 |
Why?
| | Female | 31 | 2025 | 79080 | 0.240 |
Why?
| | Cytoplasmic Granules | 6 | 1986 | 73 | 0.230 |
Why?
| | Glyburide | 6 | 1988 | 30 | 0.230 |
Why?
| | Fasting | 7 | 2005 | 280 | 0.230 |
Why?
| | Food Deprivation | 1 | 2006 | 28 | 0.230 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1403 | 0.230 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 57 | 0.230 |
Why?
| | Mitogens | 3 | 2001 | 55 | 0.230 |
Why?
| | Physical Conditioning, Animal | 2 | 2006 | 242 | 0.230 |
Why?
| | Drug Synergism | 6 | 2003 | 353 | 0.220 |
Why?
| | Fatty Acids | 2 | 2012 | 460 | 0.220 |
Why?
| | In Vitro Techniques | 15 | 2003 | 1041 | 0.220 |
Why?
| | RNA, Messenger | 8 | 2006 | 2783 | 0.220 |
Why?
| | Transferases | 4 | 1997 | 27 | 0.220 |
Why?
| | Transcription Factors | 5 | 2004 | 1728 | 0.220 |
Why?
| | Adaptor Proteins, Vesicular Transport | 3 | 2001 | 46 | 0.220 |
Why?
| | Diabetes, Gestational | 2 | 2006 | 307 | 0.220 |
Why?
| | Cell Division | 5 | 2009 | 735 | 0.220 |
Why?
| | Diabetes Complications | 2 | 2019 | 219 | 0.210 |
Why?
| | Diet, Reducing | 1 | 2005 | 90 | 0.210 |
Why?
| | Protein Subunits | 4 | 2008 | 225 | 0.210 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 48 | 0.210 |
Why?
| | Fetal Blood | 1 | 2006 | 325 | 0.210 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 36 | 0.210 |
Why?
| | Cell Line | 12 | 2008 | 2809 | 0.200 |
Why?
| | Protein Kinase C | 3 | 1996 | 250 | 0.200 |
Why?
| | ras Proteins | 2 | 2009 | 148 | 0.200 |
Why?
| | Lysophospholipids | 2 | 2001 | 80 | 0.190 |
Why?
| | Garlic | 1 | 2003 | 2 | 0.190 |
Why?
| | Sulfinic Acids | 1 | 2003 | 6 | 0.190 |
Why?
| | Up-Regulation | 1 | 2006 | 840 | 0.190 |
Why?
| | Cell Nucleus | 3 | 1995 | 584 | 0.180 |
Why?
| | Metabolic Syndrome | 3 | 2013 | 364 | 0.180 |
Why?
| | Aged | 10 | 2025 | 26251 | 0.180 |
Why?
| | Intensive Care Units | 2 | 2025 | 923 | 0.180 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 2 | 1992 | 55 | 0.170 |
Why?
| | Breast Neoplasms | 3 | 2003 | 2411 | 0.160 |
Why?
| | Plant Extracts | 1 | 2003 | 191 | 0.160 |
Why?
| | Caloric Restriction | 2 | 2012 | 133 | 0.160 |
Why?
| | Cell Cycle | 2 | 2001 | 595 | 0.160 |
Why?
| | Growth Substances | 2 | 1998 | 136 | 0.160 |
Why?
| | Nitrendipine | 7 | 1993 | 12 | 0.160 |
Why?
| | Angiotensin II | 1 | 2000 | 102 | 0.150 |
Why?
| | Cattle | 6 | 2007 | 938 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2591 | 0.150 |
Why?
| | Fetal Diseases | 1 | 2001 | 192 | 0.150 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 2 | 1996 | 51 | 0.150 |
Why?
| | Deoxy Sugars | 2 | 1989 | 2 | 0.150 |
Why?
| | Oxidative Stress | 1 | 2006 | 1367 | 0.140 |
Why?
| | Weight Loss | 1 | 2005 | 857 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2021 | 290 | 0.140 |
Why?
| | Receptor, IGF Type 1 | 1 | 1998 | 64 | 0.140 |
Why?
| | GTP-Binding Proteins | 1 | 1999 | 150 | 0.140 |
Why?
| | Serine | 2 | 2008 | 142 | 0.130 |
Why?
| | Cations | 1 | 1998 | 83 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2003 | 288 | 0.130 |
Why?
| | Aging | 5 | 1992 | 1983 | 0.130 |
Why?
| | Receptors, Somatostatin | 11 | 1986 | 24 | 0.130 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 488 | 0.130 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 1996 | 166 | 0.130 |
Why?
| | Models, Organizational | 1 | 2018 | 145 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 353 | 0.120 |
Why?
| | NF-kappa B | 1 | 2000 | 674 | 0.120 |
Why?
| | Pilot Projects | 2 | 2014 | 1878 | 0.120 |
Why?
| | Oncogene Protein v-akt | 2 | 2008 | 24 | 0.120 |
Why?
| | Young Adult | 6 | 2020 | 14240 | 0.120 |
Why?
| | Time Factors | 7 | 2006 | 7079 | 0.120 |
Why?
| | Hypertension | 3 | 2019 | 1270 | 0.120 |
Why?
| | Exocytosis | 5 | 1988 | 85 | 0.120 |
Why?
| | Life Style | 1 | 2019 | 495 | 0.120 |
Why?
| | 1-Methyl-3-isobutylxanthine | 6 | 1986 | 24 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2021 | 692 | 0.120 |
Why?
| | Fibroblasts | 6 | 2001 | 1033 | 0.120 |
Why?
| | Recombinant Proteins | 5 | 2001 | 1361 | 0.120 |
Why?
| | Potassium | 7 | 1992 | 151 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 973 | 0.110 |
Why?
| | Swine, Miniature | 2 | 2013 | 88 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 133 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2016 | 17291 | 0.110 |
Why?
| | Calcium-Transporting ATPases | 2 | 1993 | 33 | 0.110 |
Why?
| | Mice, Obese | 2 | 2009 | 68 | 0.110 |
Why?
| | Cardiovascular Agents | 1 | 2016 | 165 | 0.110 |
Why?
| | Somatomedins | 5 | 1981 | 28 | 0.110 |
Why?
| | Glycogen Synthase | 2 | 1991 | 6 | 0.110 |
Why?
| | Placenta Growth Factor | 2 | 2005 | 26 | 0.110 |
Why?
| | Prospective Studies | 4 | 2025 | 8087 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 5 | 2006 | 2533 | 0.100 |
Why?
| | Glucose Transporter Type 4 | 3 | 2003 | 39 | 0.100 |
Why?
| | Rats, Zucker | 2 | 2007 | 32 | 0.100 |
Why?
| | Thinness | 2 | 2012 | 99 | 0.100 |
Why?
| | Fatty Acid Synthases | 2 | 2006 | 23 | 0.100 |
Why?
| | Inulin | 1 | 1993 | 12 | 0.100 |
Why?
| | United States | 5 | 2021 | 16041 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 278 | 0.100 |
Why?
| | Glucose Tolerance Test | 3 | 2009 | 360 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2018 | 11744 | 0.100 |
Why?
| | Point-of-Care Systems | 1 | 2015 | 185 | 0.100 |
Why?
| | ras Guanine Nucleotide Exchange Factors | 5 | 1996 | 8 | 0.090 |
Why?
| | GRB2 Adaptor Protein | 5 | 2001 | 12 | 0.090 |
Why?
| | Guanosine Diphosphate | 4 | 1997 | 20 | 0.090 |
Why?
| | Education, Medical | 1 | 1996 | 273 | 0.090 |
Why?
| | Mice, Transgenic | 4 | 2007 | 2131 | 0.090 |
Why?
| | Insulin Antagonists | 2 | 2008 | 6 | 0.090 |
Why?
| | Guanine Nucleotide Exchange Factors | 5 | 1996 | 64 | 0.090 |
Why?
| | Cricetinae | 3 | 2001 | 295 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 102 | 0.090 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 170 | 0.090 |
Why?
| | Models, Biological | 4 | 2007 | 1758 | 0.090 |
Why?
| | Phospholipases A | 1 | 1991 | 97 | 0.090 |
Why?
| | ras GTPase-Activating Proteins | 3 | 1996 | 16 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2018 | 878 | 0.080 |
Why?
| | Prognosis | 1 | 2020 | 4331 | 0.080 |
Why?
| | ErbB Receptors | 4 | 1996 | 636 | 0.080 |
Why?
| | Transcription, Genetic | 3 | 2012 | 1429 | 0.080 |
Why?
| | PPAR gamma | 1 | 2012 | 180 | 0.080 |
Why?
| | Isoenzymes | 1 | 1991 | 294 | 0.080 |
Why?
| | GTPase-Activating Proteins | 3 | 1996 | 81 | 0.080 |
Why?
| | Flavonoids | 2 | 2004 | 85 | 0.080 |
Why?
| | Chromones | 2 | 2004 | 43 | 0.080 |
Why?
| | Renal Insufficiency | 1 | 2013 | 172 | 0.080 |
Why?
| | Membrane Proteins | 2 | 1996 | 1130 | 0.080 |
Why?
| | Oncogene Protein p21(ras) | 3 | 1994 | 11 | 0.080 |
Why?
| | Luciferases | 2 | 2000 | 153 | 0.080 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1990 | 57 | 0.080 |
Why?
| | RNA | 2 | 2009 | 925 | 0.080 |
Why?
| | Reference Values | 5 | 2002 | 787 | 0.080 |
Why?
| | Morpholines | 2 | 2004 | 130 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2009 | 6021 | 0.080 |
Why?
| | Genes, Reporter | 2 | 2000 | 273 | 0.080 |
Why?
| | Genes | 1 | 1990 | 215 | 0.080 |
Why?
| | Energy Metabolism | 3 | 2012 | 930 | 0.080 |
Why?
| | Ion Channels | 2 | 1988 | 128 | 0.080 |
Why?
| | Diet | 3 | 2013 | 1271 | 0.070 |
Why?
| | Tyrosine | 2 | 2008 | 217 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2001 | 878 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1101 | 0.070 |
Why?
| | Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2008 | 5 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 458 | 0.070 |
Why?
| | Critical Illness | 1 | 2015 | 905 | 0.070 |
Why?
| | Cyclosporins | 1 | 1988 | 71 | 0.070 |
Why?
| | Cell Movement | 2 | 2003 | 950 | 0.070 |
Why?
| | CHO Cells | 2 | 2001 | 167 | 0.070 |
Why?
| | Aorta | 1 | 1991 | 440 | 0.070 |
Why?
| | Telemedicine | 1 | 2018 | 956 | 0.070 |
Why?
| | Verapamil | 4 | 1988 | 37 | 0.070 |
Why?
| | Biological Transport | 3 | 1998 | 423 | 0.070 |
Why?
| | Erectile Dysfunction | 1 | 1988 | 35 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2012 | 533 | 0.070 |
Why?
| | Patient Readmission | 1 | 2014 | 771 | 0.070 |
Why?
| | Liver Glycogen | 3 | 1986 | 16 | 0.070 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 334 | 0.070 |
Why?
| | Calcium Channels | 1 | 1988 | 157 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8351 | 0.060 |
Why?
| | PPAR alpha | 1 | 2007 | 56 | 0.060 |
Why?
| | Fenofibrate | 1 | 2007 | 28 | 0.060 |
Why?
| | Mevalonic Acid | 2 | 1997 | 12 | 0.060 |
Why?
| | Lovastatin | 3 | 1996 | 37 | 0.060 |
Why?
| | Swine | 3 | 2013 | 821 | 0.060 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 26 | 0.060 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.060 |
Why?
| | Parathyroid Hormone | 3 | 1993 | 118 | 0.060 |
Why?
| | Farnesol | 2 | 1997 | 5 | 0.060 |
Why?
| | Gene Expression | 1 | 2012 | 1461 | 0.060 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2013 | 199 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3396 | 0.060 |
Why?
| | Eating | 1 | 1990 | 386 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2001 | 662 | 0.060 |
Why?
| | Patient Discharge | 1 | 2014 | 991 | 0.060 |
Why?
| | Exercise Tolerance | 1 | 2009 | 288 | 0.060 |
Why?
| | Prostheses and Implants | 1 | 1988 | 137 | 0.060 |
Why?
| | Hypolipidemic Agents | 1 | 2007 | 89 | 0.060 |
Why?
| | Cell Fusion | 1 | 1986 | 47 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-raf | 2 | 1996 | 46 | 0.060 |
Why?
| | Hypoglycemia | 1 | 2011 | 489 | 0.060 |
Why?
| | Bucladesine | 3 | 1992 | 19 | 0.060 |
Why?
| | Adenosine Triphosphate | 3 | 1993 | 494 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 303 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 16 | 0.060 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 630 | 0.060 |
Why?
| | Organophosphorus Compounds | 2 | 1997 | 84 | 0.060 |
Why?
| | Microscopy, Electron | 4 | 1989 | 384 | 0.060 |
Why?
| | Macromolecular Substances | 3 | 1996 | 205 | 0.060 |
Why?
| | Coated Pits, Cell-Membrane | 1 | 1985 | 3 | 0.060 |
Why?
| | Heart | 1 | 2009 | 624 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2005 | 3121 | 0.060 |
Why?
| | Interleukin-1 | 1 | 1989 | 960 | 0.060 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 3 | 2001 | 10 | 0.060 |
Why?
| | Shc Signaling Adaptor Proteins | 3 | 2001 | 10 | 0.060 |
Why?
| | Activating Transcription Factor 1 | 2 | 1995 | 9 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2006 | 187 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2008 | 454 | 0.050 |
Why?
| | Body Weight | 6 | 2002 | 964 | 0.050 |
Why?
| | Theophylline | 1 | 1985 | 41 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 169 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 262 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1754 | 0.050 |
Why?
| | Basal Metabolism | 1 | 2005 | 58 | 0.050 |
Why?
| | Peptides | 2 | 1981 | 991 | 0.050 |
Why?
| | Risk | 1 | 2007 | 917 | 0.050 |
Why?
| | Hemodynamics | 1 | 2009 | 1114 | 0.050 |
Why?
| | Endosomes | 1 | 1985 | 139 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 3 | 1993 | 429 | 0.050 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 10 | 0.050 |
Why?
| | Blotting, Northern | 3 | 1995 | 197 | 0.050 |
Why?
| | Colorado | 1 | 2014 | 4588 | 0.050 |
Why?
| | Arachidonic Acids | 3 | 1988 | 42 | 0.050 |
Why?
| | Phosphorus Radioisotopes | 2 | 1993 | 24 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 1990 | 976 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 2 | 1996 | 615 | 0.050 |
Why?
| | Breast | 1 | 2003 | 154 | 0.050 |
Why?
| | Energy Intake | 2 | 2005 | 506 | 0.050 |
Why?
| | Pregnancy | 3 | 2006 | 7217 | 0.050 |
Why?
| | Hypothyroidism | 2 | 1980 | 68 | 0.050 |
Why?
| | Streptozocin | 2 | 1992 | 22 | 0.050 |
Why?
| | Placental Hormones | 1 | 2002 | 4 | 0.050 |
Why?
| | Receptors, Progesterone | 1 | 2003 | 241 | 0.040 |
Why?
| | Cyclin D | 1 | 2001 | 8 | 0.040 |
Why?
| | Cyclin E | 1 | 2001 | 23 | 0.040 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 834 | 0.040 |
Why?
| | Carrier Proteins | 3 | 1980 | 728 | 0.040 |
Why?
| | Fetal Weight | 1 | 2001 | 53 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2001 | 1979 | 0.040 |
Why?
| | Cyclins | 1 | 2001 | 77 | 0.040 |
Why?
| | Starvation | 1 | 1981 | 21 | 0.040 |
Why?
| | Disease Models, Animal | 4 | 2013 | 4565 | 0.040 |
Why?
| | Colforsin | 3 | 1991 | 47 | 0.040 |
Why?
| | Nitric Oxide Synthase | 1 | 2001 | 233 | 0.040 |
Why?
| | Calmodulin | 3 | 1986 | 70 | 0.040 |
Why?
| | Transcriptional Activation | 2 | 2000 | 368 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2003 | 405 | 0.040 |
Why?
| | Serum Response Factor | 1 | 2000 | 33 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2001 | 121 | 0.040 |
Why?
| | Response Elements | 1 | 2000 | 84 | 0.040 |
Why?
| | Glucosamine | 1 | 2000 | 14 | 0.040 |
Why?
| | Maternal-Fetal Exchange | 1 | 2001 | 171 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2001 | 429 | 0.040 |
Why?
| | Lysosomes | 1 | 1981 | 133 | 0.040 |
Why?
| | Adenoviridae | 1 | 2001 | 196 | 0.040 |
Why?
| | Hypopituitarism | 1 | 1980 | 16 | 0.040 |
Why?
| | Son of Sevenless Proteins | 2 | 1996 | 4 | 0.040 |
Why?
| | Glycation End Products, Advanced | 1 | 2000 | 84 | 0.040 |
Why?
| | Fura-2 | 2 | 1991 | 12 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2000 | 290 | 0.040 |
Why?
| | Leptin | 1 | 2001 | 247 | 0.040 |
Why?
| | Arachidonic Acid | 3 | 1988 | 101 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 210 | 0.040 |
Why?
| | DNA Replication | 1 | 2001 | 248 | 0.040 |
Why?
| | Disease Progression | 1 | 2007 | 2857 | 0.040 |
Why?
| | Muscle Denervation | 1 | 1999 | 8 | 0.040 |
Why?
| | Aurothioglucose | 1 | 1999 | 4 | 0.040 |
Why?
| | Endocrinologists | 1 | 2019 | 12 | 0.040 |
Why?
| | Clenbuterol | 1 | 1999 | 3 | 0.040 |
Why?
| | rab3 GTP-Binding Proteins | 1 | 1999 | 4 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 1999 | 7 | 0.040 |
Why?
| | Critical Care | 1 | 2025 | 700 | 0.040 |
Why?
| | Body Composition | 3 | 2009 | 686 | 0.040 |
Why?
| | Ionomycin | 2 | 1989 | 22 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2009 | 154 | 0.040 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 1998 | 77 | 0.030 |
Why?
| | Endothelial Growth Factors | 1 | 1998 | 61 | 0.030 |
Why?
| | Sheep | 1 | 2001 | 870 | 0.030 |
Why?
| | Dogs | 1 | 2000 | 516 | 0.030 |
Why?
| | Lymphokines | 1 | 1998 | 127 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2019 | 120 | 0.030 |
Why?
| | Diabetic Neuropathies | 1 | 2019 | 100 | 0.030 |
Why?
| | Binding Sites | 2 | 1996 | 1306 | 0.030 |
Why?
| | Protein Phosphatase 2 | 2 | 1995 | 41 | 0.030 |
Why?
| | Ethanol | 1 | 1983 | 629 | 0.030 |
Why?
| | Prosencephalon | 2 | 1994 | 52 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 485 | 0.030 |
Why?
| | Half-Life | 1 | 1997 | 157 | 0.030 |
Why?
| | Magnesium | 1 | 1998 | 155 | 0.030 |
Why?
| | Rats, Wistar | 1 | 1998 | 449 | 0.030 |
Why?
| | Dinitrophenols | 3 | 1982 | 6 | 0.030 |
Why?
| | Growth Hormone-Releasing Hormone | 2 | 1988 | 19 | 0.030 |
Why?
| | Physician's Role | 1 | 2019 | 222 | 0.030 |
Why?
| | Phenytoin | 1 | 1977 | 21 | 0.030 |
Why?
| | Fetus | 1 | 2001 | 798 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1996 | 10 | 0.030 |
Why?
| | Immunosorbent Techniques | 1 | 1996 | 16 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2019 | 211 | 0.030 |
Why?
| | Protein Phosphatase 1 | 2 | 1993 | 32 | 0.030 |
Why?
| | Second Messenger Systems | 1 | 1996 | 31 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1996 | 23 | 0.030 |
Why?
| | Oxygen Consumption | 2 | 2009 | 719 | 0.030 |
Why?
| | Body Mass Index | 1 | 2005 | 2446 | 0.030 |
Why?
| | Accidental Falls | 1 | 2019 | 226 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 126 | 0.030 |
Why?
| | Prediabetic State | 1 | 2019 | 250 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 1998 | 543 | 0.030 |
Why?
| | Research Support as Topic | 1 | 1996 | 81 | 0.030 |
Why?
| | Immunoblotting | 1 | 1996 | 294 | 0.030 |
Why?
| | Rats, Inbred F344 | 2 | 1986 | 266 | 0.030 |
Why?
| | Genes, Immediate-Early | 1 | 1995 | 25 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2000 | 739 | 0.030 |
Why?
| | Immediate-Early Proteins | 1 | 1995 | 46 | 0.030 |
Why?
| | Diabetic Nephropathies | 1 | 2019 | 320 | 0.030 |
Why?
| | Off-Label Use | 1 | 2015 | 50 | 0.030 |
Why?
| | Glycogen | 1 | 1995 | 55 | 0.030 |
Why?
| | Phenotype | 1 | 2003 | 3186 | 0.030 |
Why?
| | Trypsin | 2 | 1993 | 73 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 649 | 0.030 |
Why?
| | Neurons | 2 | 1994 | 1663 | 0.030 |
Why?
| | Peptide Mapping | 1 | 1994 | 61 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2006 | 6449 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1995 | 190 | 0.030 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 1994 | 14 | 0.030 |
Why?
| | DNA | 2 | 1998 | 1418 | 0.030 |
Why?
| | ras-GRF1 | 1 | 1993 | 2 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2944 | 0.020 |
Why?
| | Chloroquine | 2 | 1986 | 54 | 0.020 |
Why?
| | Intracellular Membranes | 2 | 1985 | 76 | 0.020 |
Why?
| | Consensus | 1 | 2015 | 465 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 1996 | 456 | 0.020 |
Why?
| | Carbon Radioisotopes | 1 | 1993 | 28 | 0.020 |
Why?
| | Thapsigargin | 1 | 1993 | 20 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 283 | 0.020 |
Why?
| | Thionucleotides | 1 | 1993 | 35 | 0.020 |
Why?
| | Terpenes | 1 | 1993 | 24 | 0.020 |
Why?
| | Mutation | 1 | 2004 | 4082 | 0.020 |
Why?
| | Phenols | 1 | 1993 | 106 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1996 | 2088 | 0.020 |
Why?
| | Research | 1 | 1996 | 421 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1993 | 369 | 0.020 |
Why?
| | Hormones | 2 | 1984 | 134 | 0.020 |
Why?
| | Blood Pressure | 2 | 2009 | 1761 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1996 | 448 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 639 | 0.020 |
Why?
| | Phosphorylase a | 1 | 1992 | 1 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1996 | 693 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 199 | 0.020 |
Why?
| | Okadaic Acid | 1 | 1991 | 15 | 0.020 |
Why?
| | Ethers, Cyclic | 1 | 1991 | 11 | 0.020 |
Why?
| | Vanadates | 1 | 1991 | 17 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1992 | 128 | 0.020 |
Why?
| | Mesocricetus | 1 | 1991 | 47 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 1991 | 78 | 0.020 |
Why?
| | Cadaverine | 2 | 1982 | 2 | 0.020 |
Why?
| | Densitometry | 1 | 1991 | 36 | 0.020 |
Why?
| | Calorimetry | 1 | 2012 | 69 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 1991 | 137 | 0.020 |
Why?
| | Wheat Germ Agglutinins | 1 | 1991 | 2 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | Arteries | 1 | 2013 | 260 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 326 | 0.020 |
Why?
| | Sodium | 1 | 1992 | 196 | 0.020 |
Why?
| | Sodium Fluoride | 2 | 1981 | 15 | 0.020 |
Why?
| | Food | 1 | 1992 | 149 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1300 | 0.020 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1990 | 14 | 0.020 |
Why?
| | Membrane Potentials | 1 | 1991 | 278 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 57 | 0.020 |
Why?
| | Japan | 1 | 1990 | 149 | 0.020 |
Why?
| | Homozygote | 1 | 1990 | 196 | 0.020 |
Why?
| | Secretory Rate | 2 | 1987 | 12 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 519 | 0.020 |
Why?
| | Sphingosine | 1 | 1989 | 46 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 46 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2007 | 1030 | 0.020 |
Why?
| | Plethysmography | 1 | 2009 | 104 | 0.020 |
Why?
| | Trifluoperazine | 2 | 1987 | 3 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 124 | 0.020 |
Why?
| | Freeze Fracturing | 1 | 1988 | 4 | 0.020 |
Why?
| | Hydrostatic Pressure | 1 | 1988 | 30 | 0.020 |
Why?
| | Puberty | 1 | 2009 | 141 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 1075 | 0.020 |
Why?
| | Freezing | 1 | 1988 | 84 | 0.020 |
Why?
| | Ethers | 1 | 1987 | 19 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2009 | 419 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 5875 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2009 | 363 | 0.020 |
Why?
| | Egtazic Acid | 1 | 1987 | 37 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 438 | 0.020 |
Why?
| | Benzofurans | 1 | 1987 | 26 | 0.020 |
Why?
| | Linear Models | 1 | 2009 | 847 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 427 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 1987 | 165 | 0.020 |
Why?
| | Digitonin | 1 | 1986 | 5 | 0.010 |
Why?
| | Culture Techniques | 1 | 1986 | 65 | 0.010 |
Why?
| | Exercise Test | 1 | 2009 | 634 | 0.010 |
Why?
| | Echocardiography | 1 | 2009 | 645 | 0.010 |
Why?
| | DNA Primers | 1 | 2007 | 487 | 0.010 |
Why?
| | Glyceraldehyde | 1 | 1985 | 2 | 0.010 |
Why?
| | Pronase | 1 | 1985 | 4 | 0.010 |
Why?
| | Cell Membrane Permeability | 1 | 1986 | 88 | 0.010 |
Why?
| | Sonication | 1 | 1985 | 12 | 0.010 |
Why?
| | Heart Failure | 1 | 2019 | 2323 | 0.010 |
Why?
| | Adolescent | 4 | 2009 | 22451 | 0.010 |
Why?
| | Heart Rate | 1 | 2009 | 844 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1985 | 52 | 0.010 |
Why?
| | Golgi Apparatus | 1 | 1985 | 98 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1987 | 340 | 0.010 |
Why?
| | Biopsy | 1 | 1988 | 1073 | 0.010 |
Why?
| | Peptide Hydrolases | 1 | 1986 | 105 | 0.010 |
Why?
| | Feedback | 1 | 1986 | 180 | 0.010 |
Why?
| | Urea | 1 | 1985 | 84 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1985 | 185 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2009 | 782 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1985 | 334 | 0.010 |
Why?
| | Gold | 1 | 1985 | 116 | 0.010 |
Why?
| | Motor Activity | 1 | 2009 | 701 | 0.010 |
Why?
| | Homeostasis | 1 | 1988 | 646 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2218 | 0.010 |
Why?
| | Chick Embryo | 2 | 1994 | 132 | 0.010 |
Why?
| | Lipids | 1 | 2009 | 715 | 0.010 |
Why?
| | Organoids | 1 | 1986 | 143 | 0.010 |
Why?
| | Thyroxine | 2 | 1981 | 67 | 0.010 |
Why?
| | Endocytosis | 1 | 1984 | 168 | 0.010 |
Why?
| | 2,4-Dinitrophenol | 1 | 1982 | 8 | 0.010 |
Why?
| | Colchicine | 1 | 1982 | 20 | 0.010 |
Why?
| | Cycloheximide | 1 | 1982 | 42 | 0.010 |
Why?
| | Perfusion | 2 | 1981 | 244 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1982 | 69 | 0.010 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2002 | 26 | 0.010 |
Why?
| | Deuterium | 1 | 1982 | 101 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2009 | 3633 | 0.010 |
Why?
| | Receptors, Somatomedin | 1 | 1981 | 5 | 0.010 |
Why?
| | Nutrition Disorders | 1 | 1981 | 20 | 0.010 |
Why?
| | Purine Nucleotides | 1 | 1981 | 12 | 0.010 |
Why?
| | Intracellular Fluid | 1 | 1981 | 25 | 0.010 |
Why?
| | Radioisotopes | 1 | 1981 | 37 | 0.010 |
Why?
| | Biotransformation | 1 | 1981 | 61 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 1980 | 75 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1981 | 533 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 1980 | 87 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1980 | 277 | 0.010 |
Why?
| | Growth Disorders | 1 | 1979 | 88 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 1988 | 5397 | 0.010 |
Why?
| | Inflammation | 1 | 2009 | 2915 | 0.010 |
Why?
| | 11-Hydroxycorticosteroids | 1 | 1977 | 1 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1996 | 38 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1995 | 34 | 0.010 |
Why?
| | Genes, fos | 1 | 1995 | 26 | 0.010 |
Why?
| | Child | 2 | 2009 | 22638 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1981 | 582 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1996 | 561 | 0.010 |
Why?
| | Neurites | 1 | 1994 | 51 | 0.010 |
Why?
| | Microinjections | 1 | 1994 | 92 | 0.010 |
Why?
| | Protein Binding | 1 | 1980 | 2239 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1994 | 193 | 0.010 |
Why?
| | Base Sequence | 1 | 1995 | 2119 | 0.010 |
Why?
| | Antibodies | 1 | 1994 | 395 | 0.010 |
Why?
| | Cell Survival | 1 | 1994 | 1102 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 2835 | 0.010 |
Why?
| | Hydroxymercuribenzoates | 1 | 1987 | 1 | 0.000 |
Why?
| | Dantrolene | 1 | 1987 | 5 | 0.000 |
Why?
| | Oleic Acids | 1 | 1987 | 12 | 0.000 |
Why?
| | Lipoxygenase Inhibitors | 1 | 1987 | 34 | 0.000 |
Why?
| | Oleic Acid | 1 | 1987 | 40 | 0.000 |
Why?
| | Child, Preschool | 1 | 1980 | 11888 | 0.000 |
Why?
| | Membrane Fluidity | 1 | 1984 | 8 | 0.000 |
Why?
| | Diterpenes | 1 | 1984 | 26 | 0.000 |
Why?
| | Membrane Lipids | 1 | 1984 | 81 | 0.000 |
Why?
| | Glucagon | 1 | 1984 | 114 | 0.000 |
Why?
| | Adenine Nucleotides | 1 | 1982 | 21 | 0.000 |
Why?
| | Phospholipids | 1 | 1984 | 215 | 0.000 |
Why?
| | Adenosine Triphosphatases | 1 | 1982 | 158 | 0.000 |
Why?
| | Nephrectomy | 1 | 1981 | 169 | 0.000 |
Why?
| | Propylthiouracil | 1 | 1979 | 6 | 0.000 |
Why?
| | Hypophysectomy | 1 | 1979 | 12 | 0.000 |
Why?
| | Puromycin | 1 | 1979 | 10 | 0.000 |
Why?
| | Radioligand Assay | 1 | 1979 | 34 | 0.000 |
Why?
| | Kidney | 1 | 1981 | 1491 | 0.000 |
Why?
|
|
Draznin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|